Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck/Schering's Zocor/Zetia fixed-dose combo is likely to have coverage in one of the top two tiers in up to 50% of managed care plans six to 12 months post-launch, a Prudential survey finds. Crestor has coverage in top two tiers for about 30% of plans after one year on the market.